Testing and analysis.
FDA also supports efforts to understand more fully how nanotechnology may contribute to the development of new treatments.
FDA is collaborating with NIST and the National Cancer Institute Nanotechnology Characterization Laboratory to develop characterization
assays and methods for preclinical and early clinical testing of such products as a way to better understand their promise
for providing more effective and less toxic cancer therapies. FDA has established a Nanotechnology Task Force and Nanotechnology
Interest Group of review scientists with expertise in this area to provide input on product development.
And, as part of efforts to prevent the spread of transmissible spongiform encephalopathy, or mad cow disease, FDA scientists
are collaborating with colleagues in other government agencies, academia, and industry to develop and assess technologies
able to identify prion contamination of biological products. Such tests could be valuable in ensuring the purity of biotechnological
manufacturing processes, as well as for screening blood and tissue.
is Pharmaceutical Technology's Washington editor, 7715 Rocton Ave., Chevy Chase, MD 20815, tel. 301.656.4634, email@example.com